Literature DB >> 28470574

TFF3 Expression as Stratification Marker in Borderline Epithelial Tumors of the Ovary.

Ahmed El-Balat1, Iryna Schmeil2, Thomas Karn2, Sven Becker2, Nicole Sänger2, Uwe Holtrich2, Ruza Arsenic3.   

Abstract

Borderline tumors (BOT) of the ovary account for 10% to 20% of ovarian neoplasms. Like ovarian cancer, BOT encompass several different histological subtypes (serous, mucinous, endometrioid, clear cell, transitional cell and mixed) with serous (SBOT) and mucinous (MBOT) the most common. Current hypotheses suggest low-grade serous carcinoma may develop in a stepwise fashion from SBOT whereas the majority of high grade serous carcinomas develop rapidly presumably from inclusion cysts or ovarian surface epithelium. The pathogenesis of mucinous ovarian tumors is still puzzling. Molecular markers could help to better define relationships between such entities. Trefoil factor-3 (TFF3) is an estrogen-regulated gene associated with prognosis in different types of cancer. It has also been included in a recent marker panel predicting subtypes of ovarian carcinoma. We analyzed the expression of TFF3 by immunohistochemistry in a cohort of 137 BOT and its association with histopathological features. Overall expression rate of TFF3 was 21.9%. None of the BOT with serous and endometrioid histology displayed strong TFF3 expression. On the other hand, TFF3 was highly expressed in 61.4% of MBOT cases and 33.3% of BOT with mixed histology (P < 0.001) suggesting a potential function of the protein in that subtypes. Associations of TFF3 expression with FIGO stage and micropapillary pattern were significant in the overall cohort but confounded by their correlation with histological subtypes. The highly specific expression of TFF3 in MBOT may help to further clarify potential relationships of tumors with mucinous histology and warrants further studies.

Entities:  

Keywords:  Borderline tumors; Histological subtypes; Ovarian cancer; Prognosis

Mesh:

Substances:

Year:  2017        PMID: 28470574     DOI: 10.1007/s12253-017-0240-4

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  37 in total

1.  Subclassification of serous borderline tumors of the ovary into benign and malignant types. A clinicopathologic study of 65 advanced stage cases.

Authors:  J D Seidman; R J Kurman
Journal:  Am J Surg Pathol       Date:  1996-11       Impact factor: 6.394

Review 2.  Borderline epithelial tumors of the ovary.

Authors:  William R Hart
Journal:  Mod Pathol       Date:  2005-02       Impact factor: 7.842

Review 3.  Molecular pathogenesis of ovarian borderline tumors: new insights and old challenges.

Authors:  Ie-Ming Shih; Robert J Kurman
Journal:  Clin Cancer Res       Date:  2005-10-15       Impact factor: 12.531

4.  DNA ploidy; the most important prognostic factor in patients with borderline tumors of the ovary.

Authors:  J. Kaern; C.G. Tropé; G.B. Kristensen; V.M. Abeler; E.O. Pettersen
Journal:  Int J Gynecol Cancer       Date:  1993-11       Impact factor: 3.437

5.  Calculator for ovarian carcinoma subtype prediction.

Authors:  Steve E Kalloger; Martin Köbel; Samuel Leung; Erika Mehl; Dongxia Gao; Krista M Marcon; Christine Chow; Blaise A Clarke; David G Huntsman; C Blake Gilks
Journal:  Mod Pathol       Date:  2010-12-03       Impact factor: 7.842

6.  Mutation of K-ras protooncogene in human ovarian epithelial tumors of borderline malignancy.

Authors:  S C Mok; D A Bell; R C Knapp; P M Fishbaugh; W R Welch; M G Muto; R S Berkowitz; S W Tsao
Journal:  Cancer Res       Date:  1993-04-01       Impact factor: 12.701

7.  PAX2, PAX8 and CDX2 Expression in Metastatic Mucinous, Primary Ovarian Mucinous and Seromucinous Tumors and Review of the Literature.

Authors:  D Ates Ozdemir; A Usubutun
Journal:  Pathol Oncol Res       Date:  2016-01-21       Impact factor: 3.201

8.  Exploring the histogenesis of ovarian mucinous and transitional cell (Brenner) neoplasms and their relationship with Walthard cell nests: a study of 120 tumors.

Authors:  Jeffrey D Seidman; Fatemeh Khedmati
Journal:  Arch Pathol Lab Med       Date:  2008-11       Impact factor: 5.534

Review 9.  Are trefoil factors oncogenic?

Authors:  Jo K Perry; Nagarajan Kannan; Prudence M Grandison; Murray D Mitchell; Peter E Lobie
Journal:  Trends Endocrinol Metab       Date:  2007-12-03       Impact factor: 12.015

10.  Trefoil Factor-3 (TFF3) Stimulates De Novo Angiogenesis in Mammary Carcinoma both Directly and Indirectly via IL-8/CXCR2.

Authors:  Wai-Hoe Lau; Vijay Pandey; Xiangjun Kong; Xiao-Nan Wang; ZhengSheng Wu; Tao Zhu; Peter E Lobie
Journal:  PLoS One       Date:  2015-11-11       Impact factor: 3.240

View more
  2 in total

1.  Diagnostic and prognostic role of TFF3, Romo-1, NF-кB and SFRP4 as biomarkers for endometrial and ovarian cancers: a prospective observational translational study.

Authors:  Hasan Turan; Salvatore Giovanni Vitale; Ilker Kahramanoglu; Luigi Della Corte; Pierluigi Giampaolino; Asli Azemi; Sinem Durmus; Veysel Sal; Nedim Tokgozoglu; Tugan Bese; Macit Arvas; Fuat Demirkiran; Remise Gelisgen; Sennur Ilvan; Hafize Uzun
Journal:  Arch Gynecol Obstet       Date:  2022-04-24       Impact factor: 2.344

Review 2.  The Diagnosis, Treatment, Prognosis and Molecular Pathology of Borderline Ovarian Tumors: Current Status and Perspectives.

Authors:  Yu Sun; Juan Xu; Xuemei Jia
Journal:  Cancer Manag Res       Date:  2020-05-19       Impact factor: 3.989

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.